AU2003265853A1 - Hedgehog antagonists, methods and uses related thereto - Google Patents

Hedgehog antagonists, methods and uses related thereto

Info

Publication number
AU2003265853A1
AU2003265853A1 AU2003265853A AU2003265853A AU2003265853A1 AU 2003265853 A1 AU2003265853 A1 AU 2003265853A1 AU 2003265853 A AU2003265853 A AU 2003265853A AU 2003265853 A AU2003265853 A AU 2003265853A AU 2003265853 A1 AU2003265853 A1 AU 2003265853A1
Authority
AU
Australia
Prior art keywords
methods
hedgehog antagonists
uses related
hedgehog
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003265853A
Other versions
AU2003265853A8 (en
Inventor
Henryk K. Dudek
Irina Karavanov
Karen Kotkow
Carmen Pepicelli
Lee Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU2003265853A8 publication Critical patent/AU2003265853A8/en
Publication of AU2003265853A1 publication Critical patent/AU2003265853A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2003265853A 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto Abandoned AU2003265853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40714502P 2002-08-29 2002-08-29
US60/407,145 2002-08-29
PCT/US2003/027279 WO2004020599A2 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Publications (2)

Publication Number Publication Date
AU2003265853A8 AU2003265853A8 (en) 2004-03-19
AU2003265853A1 true AU2003265853A1 (en) 2004-03-19

Family

ID=31978427

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003265853A Abandoned AU2003265853A1 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Country Status (2)

Country Link
AU (1) AU2003265853A1 (en)
WO (1) WO2004020599A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
WO2005097207A2 (en) 2004-03-26 2005-10-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
EP1862180A4 (en) * 2005-03-25 2010-09-15 Takeda Pharmaceutical Prophylactic/therapeutic agent for cancer
EP1966130B1 (en) 2005-12-23 2013-12-11 Zealand Pharma A/S Modified lysine-mimetic compounds
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
CN104059124A (en) 2007-12-27 2014-09-24 无限药品股份有限公司 Methods For Stereoselective Reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0908417B1 (en) 2008-02-26 2022-01-11 Takeda Pharmaceutical Company Limited COMPOUND AND USE OF COMPOUND
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
CN102202737B (en) 2008-11-03 2014-03-26 伊莱利利公司 Disubstituted 2,3-phthalazine hedgehog pathway antagonists
JP5518088B2 (en) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー Tetrasubstituted pyridazine hedgehog pathway antagonist
JP5518887B2 (en) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー Tetrasubstituted pyridazine hedgehog pathway antagonist
AR077014A1 (en) 2009-06-19 2011-07-27 Lilly Co Eli COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
EP2462115B1 (en) 2009-08-05 2016-01-06 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011024873A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
EP2471793B1 (en) 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011024869A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
WO2011024872A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
CN103002738A (en) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 Chemical compounds, compositions and methods for kinase modulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TWI546305B (en) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6027610B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
CN103946226A (en) 2011-07-19 2014-07-23 无限药品股份有限公司 Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ718430A (en) 2013-10-04 2021-12-24 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104906113A (en) * 2014-03-12 2015-09-16 淄博赛维医药技术有限公司 Antitumor medicine
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JP6989864B2 (en) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Also Published As

Publication number Publication date
WO2004020599A2 (en) 2004-03-11
AU2003265853A8 (en) 2004-03-19
WO2004020599A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AU2003265853A1 (en) Hedgehog antagonists, methods and uses related thereto
EP3308772B8 (en) Inhalable epinephrine
AU9684401A (en) Hedgehog antagonists, methods and uses related thereto
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2003262857A1 (en) Selective feature activation
AU2003273249A1 (en) Laminate structures, methods for production thereof and uses therefor
AU2003226094A1 (en) Compounds and methods
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
AU2003268204A1 (en) Personal area networks
AU2003207199A1 (en) Structure, method of manufacturing the same, and device using the same
AU2003230395A1 (en) Micro-support structures
AU2003270680A1 (en) Tubular structures and methods for making the same
AU2003299943A1 (en) Heterocycles and uses thereof
AU2003209469A1 (en) Security arrangement
AU2003227976A1 (en) Meeting aid
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003232244A1 (en) Nanofiller, production, and use
EP1517879A4 (en) Aminoalkylphenols, methods of using and making the same
AU2002952559A0 (en) New use
AU2003301628A1 (en) Key unit, method for marking key top, and method for manufacturing key unit using the same
AU2003214836A1 (en) Combined gemstone
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
PL373738A1 (en) Immunosuppressant compounds, methods and uses related thereto
AU2003299336A1 (en) Diphosphines, preparation and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase